NOBIVAC® Canine 1-DAPPv | Merck Animal Health USA

Canine 1-DAPPv

A proven foundation for vaccine protocols. Canine 1-DAPPv is a combination vaccine approved for protection against canine distemper virus, adenovirus type 1 and 2, canine parainfluenza virus, and canine parvovirus.

NOBIVAC^® CANINE 1-DAPPv provides protection against:

Canine Distemper Virus, Canine Adenovirus type 1, Canine Adenovirus type 2, Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).

Protects against all known strains of CPV, including CPV-2c^2,3
High antigenic mass (titer), low passage parvovirus vaccine
Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1 and 2, parainfluenza and parvovirus in 1 formula
First to publish data showing protection against CPV-2c challenge²
Multiple studies demonstrate the ability to override maternal antibodies¹

PRODUCT LABEL

Indications:

Shown to be effective for the vaccination against canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease), canine parainfluenza virus and canine parvovirus.

ADMINISTRATION AND DOSAGE

Subcutaneous or intramuscular injection
Primary vaccination may begin as early as 6 weeks
Repeat dose at 2 to 4 weeks later.
Two doses are required for primary immunization.
Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
Available in a 25 x 1 mL dose presentation

ALSO AVAILABLE IN OTHER FORMULATIONS

DISEASE INFORMATION

MORBIDITY THREATS

Signs vary from a slight fever to death.
The mortality rate ranges from 10%–30%.
Severely infected dogs may develop convulsions from forebrain damage.
Paresis, ataxia and central blindness have also been described.
In ~25% of recovered dogs, bilateral corneal opacity develops.

SPREADING DISEASE

The virus is spread in the feces, urine, blood, saliva, and nasal discharge of infected dogs.
Contracted through the mouth or nose, where it replicates in the tonsils.
The incubation period is 4 to 7 days.

DIAGNOSIS

Abrupt onset of illness and bleeding suggest ICH, although clinical evidence is not always sufficient to differentiate ICH from distemper (see Canine Distemper).

Efficacy & Comparisons

D–CANINE DISTEMPER VIRUS (CDV)

Onderstepoort-type strain in Nobivac^® vaccines provides a high level of safety¹

A–CANINE ADENOVIRUS TYPE 2 (CAV-2)

Protection against CAV-1 and CAV-2 without the side effects associated with modified live CAV-1 vaccines¹

P–CANINE PARAINFLUENZA VIRUS (CPIV)

Systemic administration stimulates a strong IgG response¹

PV-CANINE PARVOVIRUS (CPV)

Protect against all known strains of Canine Parvovirus (CPV), including CPV-2C^2,7,8

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ²

No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains²
First published data showing protection against CPV-2c challenge²
All vaccinated puppies were protected from disease
All control puppies developed disease and 50% died or were euthanized

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ²

No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains²
First published data showing protection against CPV-2c challenge²
All vaccinated puppies were protected from disease
All control puppies developed disease and 50% died or were euthanized